On Monday, Pfizer filed an antitrust lawsuit against Danish pharmaceutical company Novo Nordisk, alleging that Novo's $9 billion bid for biotech firm Metsera is a calculated move to hinder competition in the obesity drug sector. Pfizer had earlier agreed to a $7.3 billion acquisition of Metsera, which is developing a promising new obesity drug.

Metsera's board has sided with Novo, declaring their proposal superior and giving Pfizer a short deadline to improve its offer. The Delaware court received a plea from Metsera urging the denial of Pfizer's request for a temporary restraining order to block Novo's bid, highlighting Pfizer's delayed action despite being aware of the offer.

The lawsuit contends that Novo's offer, which includes a substantial upfront payment, aims to halt Metsera's pr

See Full Page